User profiles for Zachary L Skidmore
 | Zachary L. SkidmoreStaff Scientist, The Genome Institute, Washington University St. Louis Verified email at genome.wustl.edu Cited by 3234 |
[HTML][HTML] CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
CIViC is an expert-crowdsourced knowledgebase for Clinical Interpretation of Variants in
Cancer describing the therapeutic, prognostic, diagnostic and predisposing relevance of …
Cancer describing the therapeutic, prognostic, diagnostic and predisposing relevance of …
DGIdb 2.0: mining clinically relevant drug–gene interactions
The Drug–Gene Interaction Database (DGIdb, www.dgidb.org ) is a web resource that
consolidates disparate data sources describing drug–gene interactions and gene druggability. It …
consolidates disparate data sources describing drug–gene interactions and gene druggability. It …
Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus–unrelated head and neck cancer: a multicenter, phase II trial
…, KM Campbell, AM Egloff, P Zolkind, ZL Skidmore… - Clinical Cancer …, 2020 - AACR
Purpose: Pembrolizumab improved survival in patients with recurrent or metastatic head
and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if …
NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor–positive breast cancer
Purpose: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor–positive
(ER + ) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
(ER + ) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) …
GenVisR: genomic visualizations in R
Visualizing and summarizing data from genomic studies continues to be a challenge. Here,
we introduce the GenVisR package to addresses this challenge by providing highly …
we introduce the GenVisR package to addresses this challenge by providing highly …
[PDF][PDF] Optimizing cancer genome sequencing and analysis
Tumors are typically sequenced to depths of 75x–100x (exome) or 30x–50x (whole genome).
We demonstrate that current sequencing paradigms are inadequate for tumors that are …
We demonstrate that current sequencing paradigms are inadequate for tumors that are …
[HTML][HTML] The prognostic effects of somatic mutations in ER-positive breast cancer
Here we report targeted sequencing of 83 genes using DNA from primary breast cancer
samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) …
samples from 625 postmenopausal (UBC-TAM series) and 328 premenopausal (MA12 trial) …
[HTML][HTML] Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
…, ZL Skidmore, K Krysiak, A Ramu, L Trani… - Nature …, 2018 - nature.com
Nearly all patients with small cell lung cancer (SCLC) eventually relapse with chemoresistant
disease. The molecular mechanisms driving chemoresistance in SCLC remain un-…
disease. The molecular mechanisms driving chemoresistance in SCLC remain un-…
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
…, A Joseph, ZL Skidmore… - Blood, The Journal …, 2019 - ashpublications.org
Immune checkpoint inhibitors are a powerful new tool in the treatment of cancer, with prolonged
responses in multiple diseases, including hematologic malignancies, such as Hodgkin …
responses in multiple diseases, including hematologic malignancies, such as Hodgkin …
A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor–positive metastatic breast cancer
Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and
preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in …
preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in …